BUSINESS
How Natco defied the odds to rise up India's pharma ladder
Copaxone is expected to deliver another windfall in FY19 for Natco, before tapering-off slowly in FY20 with the launches from other generic rivals.
BUSINESS
Pharma weekly wrap: Fortis re-opens bid process, Delhi govt proposes price caps; cos report Q4 earnings
Fortis board shortlisted four interested parties Munjal-Burmans, IHH Healthcare, Manipal-TPG and Radiant Life Care to participate in the bidding process.
BUSINESS
Delhi govt proposals to rein-in pvt hospitals may hit legal road blocks
Analysts say some of Delhi government proposals may hit a legal stalemate as they may not fit in well with the Delhi Nursing Homes Registration Nursing Act, 1953 until unless it is suitably amended and even expressed doubts whether it will get nod of Lieutenant Governor.
BUSINESS
Fortis board shortlists four bidders to participate in the sale process
Following due diligence, the bidders will have to submit bids by June 14
BUSINESS
Lupin launches specialty women health drug Solosec in US
Analysts estimate the drug to hit peak sales of USD 100 million per annum in next four years
BUSINESS
Fortis postpones Q4 earnings citing deliberations over outcome of internal investigation
Fortis' Q2 and Q3 earnings were reported together after getting delayed several times as the statutory auditor refused to sign the accounts.
BUSINESS
Indian drug cos scramble to comply with new data regulation in EU, the second largest market for exports
EU is second largest destination for pharmaceutical exports constituting about 12 percent of total Indian pharmaceutical exports of USD 17.27 billion in 2017-18
BUSINESS
L&T says private sector capex is still muted, revival could take two years
L&T said it had to prune its order book by Rs 16,000 crore as some developers in real estate faced liquidity issues.
BUSINESS
Pharma Weekly Wrap: Never-ending Fortis saga, Q4 numbers hog limelight
In the week to come, Aurobindo Pharma, Glenmark, Apollo Hospitals and Fortis Healthcare will declare their March quarter numbers.
BUSINESS
Indian pharma market grows 7.8 percent in December on uptake in respiratory and anti-infectives
The IPM reported sales of Rs 10000 crore for December. The IPM stood at Rs 1.16 trillion for the moving annual total (MAT) ended December, reporting a YoY growth of 5.5 percent.
BUSINESS
Pharma wrap: Pharma stocks gain on BJP retaining Gujarat, medical device makers open to regulation
Pharma stocks posted gains in the past week with the BJP retaining power in the Gujarat assembly elections. Here's what kept the sector buzzing
BUSINESS
We support govt's move to regulate trade margins: MNC devices lobby
MTaI called for a more “nuanced approach” to regulation of medical devices taking into account the costs incurred on “services and support required for the devices”.
BUSINESS
Hester Biosciences plans to raise fresh funds for its proposed African animal vaccine plant
The proposed manufacturing plant expected to come up in Tanzania will manufacture vaccines against African specific bacterial and virus strains causing disease in cattle, goat and sheep.
BUSINESS
Dr Reddy's board gives nod to induct third generation leadership into the company
Dr Reddy's Laboratories board has given green signal to induct Akhil Ravi, the son-in-law of GV Prasad, Co-Chairman, and CEO - of Dr Reddy's into the company management.
BUSINESS
Wockhardt to offer its Waluj formulation facility for US FDA inspection in early 2018
The company’s formulation units at Chikalthana and Waluj in Maharashtra have been under the USFDA’s import alert since 2013, while its bulk drug plant at Ankleshwar in Gujarat was also issued an import alert.
BUSINESS
SC asks govt expert body to review banned FDC drugs before taking further action
The recommendations of the DTAB or its expert sub-committee would have to be made to the Central Government within six months, after which the government will act further if and where necessary.
BUSINESS
Homeopathy sees resurgence with govt support & more people trying alternate medicines
B Jain Pharmaceuticals, the New Delhi-based maker of homeopathic ingredients and formulations, says it sees resurgence of homeopathy in India backed by more people willing to try alternative therapies and government's own efforts to promote traditional medical practices.
BUSINESS
Antibiotics & asthma drugs help Indian pharma market to grow at 8.1% in Nov
The highest growth for any month so far in FY18, helped by improved uptake in anti-infectives, respiratory and gastrointestinal segments, despite gradual recovery from the disruption caused by GST transition, according to market research firm AIOCD-AWACS.
BUSINESS
Pharma Weekly Wrap: Pharma stocks rebound this week on buying interest
The hospital stocks remained stable despite the ongoing developments related to Delhi government cancelling license of Max Hospital Shalimar Bagh and Harayana government removing Gurugram’s Fortis Hospital from the list of empanelled hospitals.
BUSINESS
Max Hospital Shalimar Bagh licence cancelled, calls govt’s move too ‘harsh’
The Delhi government on Friday cancelled the licence of Max Hospital Shalimar Bagh on alleged “gross medical negligence” by hospital authorities in a case related to a newborn declared dead by hospital but later found alive.
BUSINESS
US FDA eases throttle on generics with highest-ever approvals in a single month
The record push in terms of approvals is part of US FDA efforts to lower prescription drug costs, an election promise of US President Donald Trump.
BUSINESS
Biocon creates new subsidiary to unlock value of its biologics business
The biologics business consists biosimilars that include monoclonal antibodies and recombinant insulins and novel biologics
BUSINESS
Pharma stocks remain subdued this week as investors book profit, Biocon stands tall
The BSE Healthcare index dropped 2.4 percent in the past week, while the BSE Sensex declined 1.3 percent
BUSINESS
US gives nod to Biocon-Mylan's biosimilar of cancer drug Herceptin, revenues expected from FY19
Ogivri is the first FDA-approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon’s joint portfolio approved in the US
